Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telotristat etiprate - TerSera Therapeutics

Drug Profile

Telotristat etiprate - TerSera Therapeutics

Alternative Names: LP-778914; LX-1032; LX-1606; LX1032 hippurate; LX1606 hippurate; Telotristat ethyl; Xermelo

Latest Information Update: 17 Aug 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lexicon Pharmaceuticals
  • Developer Ipsen; Lexicon Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Tryptophan hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant carcinoid syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant carcinoid syndrome
  • Phase II Biliary cancer; Neuroendocrine tumours
  • Preclinical Cholangiocarcinoma; Colorectal cancer; Liposarcoma
  • Discontinued Ulcerative colitis

Most Recent Events

  • 19 Jul 2021 Phase-II clinical trials in Neuroendocrine tumours (In adults, In the elderly, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, Combination therapy) in USA (PO) (NCT04543955)
  • 03 Mar 2021 Big Ten Cancer Research Consortium and TerSera Therapeutics initiates a phase II NET-PACS trial for Malignant carcinoid syndrome (Adjunctive treatment, Treatment-experienced) in USA (PO, Tablet) (NCT04713202)
  • 21 Jan 2021 Big Ten Cancer Research Consortium (Pashtoon Kasi, MD, MS) and TerSera Therapeutics plans a phase II NET-PACS trial for Malignant carcinoid syndrome in February 2021 (NCT04713202),
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top